{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:01:48Z","timestamp":1791223308225,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":2562,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1038\/ki.2008.356","type":"journal-article","created":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T16:44:39Z","timestamp":1218041079000},"page":"1385-1393","source":"Crossref","is-referenced-by-count":365,"title":["Bisphosphonate nephrotoxicity"],"prefix":"10.1016","volume":"74","author":[{"given":"Mark A.","family":"Perazella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen S.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1038\/ki.2008.356_bb0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"key":"10.1038\/ki.2008.356_bb0015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","article-title":"Renal safety and efficay on i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years","volume":"10","author":"Guarneri","year":"2005","journal-title":"Oncologist"},{"key":"10.1038\/ki.2008.356_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1038\/ki.2008.356_bb0025","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1038\/ki.2008.356_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.10-90001-14","article-title":"Renal safety of ibandronate","volume":"10","author":"Jackson","year":"2005","journal-title":"Oncologist"},{"key":"10.1038\/ki.2008.356_bb0035","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0022-2275(20)41388-4","article-title":"Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis","volume":"33","author":"Amin","year":"1992","journal-title":"J Lipid Res"},{"key":"10.1038\/ki.2008.356_bb0040","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphophosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1038\/ki.2008.356_bb0045","first-page":"143","article-title":"Protein prenylation: molecular mechanisms and dysfunctional consequences","volume":"37","author":"Zhang","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1038\/ki.2008.356_bb0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1083\/jcb.142.2.573","article-title":"Integrin-mediated signals regulated by members of the rho family of GTPases","volume":"142","author":"Clark","year":"1998","journal-title":"J Cell Biol"},{"key":"10.1038\/ki.2008.356_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0092-8674(92)90164-8","article-title":"The small GTP-binding protein rac regulates growth factor-induced membrane ruffling","volume":"70","author":"Ridley","year":"1992","journal-title":"Cell"},{"key":"10.1038\/ki.2008.356_bb0060","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1242\/jcs.108.6.2285","article-title":"The small GTP-binding protein rho p21 is involved in bone resorption by regulating cytoskeletal organization in osteoclasts","volume":"108","author":"Zhang","year":"1995","journal-title":"J Cell Sci"},{"key":"10.1038\/ki.2008.356_bb0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1042\/bj3030303","article-title":"Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum","volume":"303","author":"Rogers","year":"1994","journal-title":"Biochem J"},{"key":"10.1038\/ki.2008.356_bb0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s002239900606","article-title":"Etidronate (EHDP) inhibits osteoclastic bone resorption, promotes apoptosis, and disrupts actin rings in isolate-mature osteoclasts","volume":"64","author":"Hiroi-Furuyama","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"10.1038\/ki.2008.356_bb0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1038\/ki.2008.356_bb0080","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: a clinical pharmacological and pharmacoknetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"Suppl","key":"10.1038\/ki.2008.356_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"19","author":"Body","year":"2005","journal-title":"Oncologist"},{"key":"10.1038\/ki.2008.356_bb0090","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1038\/ki.2008.356_bb0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","article-title":"Two years\u2019 effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause","volume":"4","author":"Thiebaud","year":"1994","journal-title":"Osteoporos Int"},{"key":"10.1038\/ki.2008.356_bb0100","first-page":"315","article-title":"Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis","volume":"60","author":"Heijckmann","year":"2002","journal-title":"Neth J Med"},{"key":"10.1038\/ki.2008.356_bb0105","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal osteoporosis: 1 year findings from the DIVA study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1038\/ki.2008.356_bb0110","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1038\/ki.2008.356_bb0115","series-title":"Bone health and osteoporosis: a report of the Surgeon general","author":"US Department of Health and Human Services","year":"2004"},{"key":"10.1038\/ki.2008.356_bb0120","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2008.356_bb0125","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1038\/ki.2008.356_bb0130","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1038\/ki.2008.356_bb0135","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","article-title":"Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long term comparative study","volume":"14","author":"Ringe","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1038\/ki.2008.356_bb0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","article-title":"Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models","volume":"80","author":"Green","year":"1997","journal-title":"Pharmacol Toxicol"},{"key":"10.1038\/ki.2008.356_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0300-483X(90)90088-X","article-title":"Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1, bisphosphonate (APD), in rats and mice","volume":"65","author":"Cal","year":"1990","journal-title":"Toxicology"},{"key":"10.1038\/ki.2008.356_bb0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0300-483X(78)90539-5","article-title":"Urinary gamma-glutamyl transferase in renal toxicology of the rat","volume":"11","author":"Braun","year":"1978","journal-title":"Toxicology"},{"key":"10.1038\/ki.2008.356_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0300-483X(03)00257-9","article-title":"The renal effects of minimally nephrotoxic doses of ibandronate following single and intermittent administration in rats","volume":"191","author":"Pfister","year":"2003","journal-title":"Toxicology"},{"key":"10.1038\/ki.2008.356_bb0160","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1038\/ki.2008.356_bb0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2005.pto_160.x","article-title":"Acute nephrotoxicity of three intravenous bisphosphonates in the rat","volume":"97","author":"Pfister","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1038\/ki.2008.356_bb0170","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"Markowitz","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.356_bb0175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x","article-title":"Podocyte injury associated glomerulopathies induced by pamidronate","volume":"65","author":"Barri","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.356_bb0180","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","article-title":"Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma","volume":"119","author":"Desikan","year":"2002","journal-title":"Brit J Haematol"},{"key":"10.1038\/ki.2008.356_bb0185","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08998280.2007.11928298","article-title":"Reversibility of pamidronate-associated glomerulosclerosis","volume":"20","author":"Shreedhara","year":"2007","journal-title":"Proc (Baylor Univ Med Cent)"},{"key":"10.1038\/ki.2008.356_bb0190","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","article-title":"Nephrotic syndrome after treatment with pamidronate","volume":"39","author":"Markowitz","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.356_bb0195","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1053\/ajkd.2002.33933","article-title":"Pamidronate-associated nephrotoxicity in a patient with Langerhan's histiocytosis","volume":"40","author":"Lockridge","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2008.356_bb0200","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/gfg567","article-title":"Collapsing glomerulopathy induced by long-term treatment with standard dose pamidronate in a myeloma patient","volume":"19","author":"Kunin","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.356_bb0205","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.ki.5000144","article-title":"Multiple myeloma, nephrotic syndrome, and crystalloid inclusions in podocytes","volume":"69","author":"Nasr","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.356_bb0210","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfm209","article-title":"Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient","volume":"22","author":"Bodmer","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.356_bb0215","first-page":"E18","article-title":"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity","volume":"41","author":"Banerjee","year":"2003","journal-title":"Am J Kidn Dis"},{"key":"10.1038\/ki.2008.356_bb0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5414\/CNP61063","article-title":"Pamidronate-induced nephrotoxic tubular necrosis \u2013 a case report","volume":"61","author":"Smetana","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2008.356_bb0225","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ndt\/gfg044","article-title":"Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism","volume":"18","author":"Buysschaert","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2008.356_bb0230","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.356_bb0235","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"New Engl J Med"},{"key":"10.1038\/ki.2008.356_bb0240","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1038\/ki.2008.356_bb0245","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2008.356_bb0250","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1038\/ki.2008.356_bb0255","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E589","article-title":"Zoledronic acid and renal toxicity: data from French dverse reporting database","volume":"39","author":"Munier","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1038\/ki.2008.356_bb0260","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.22504","article-title":"The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"key":"10.1038\/ki.2008.356_bb0265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1038\/ki.2008.356_bb0270","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1038\/ki.2008.356_bb0275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2354.2005.00641.x","article-title":"Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trail results","volume":"15","author":"Body","year":"2005","journal-title":"Eur J Cancer Cure"},{"key":"10.1038\/ki.2008.356_bb0280","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1038\/ki.2008.356_bb0285","first-page":"S45","article-title":"Renal safety of ibandronate in multiple myeloma patients with renal deterioration","volume":"31","author":"Bergner","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/ki.2008.356_bb0290","first-page":"463","article-title":"Ibandronate in the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure","volume":"13","author":"Henrich","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1038\/ki.2008.356_bb0295","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01625440","article-title":"Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis","volume":"1","author":"Fromm","year":"1991","journal-title":"Osteoporos Int"},{"key":"10.1038\/ki.2008.356_bb0300","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol"},{"issue":"Supp 2","key":"10.1038\/ki.2008.356_bb0305","first-page":"422","article-title":"Renal tolerability of intravenous ibandronate allows administration by short injection","volume":"65","author":"Miller","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1038\/ki.2008.356_bb0310","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.ki.5001903","article-title":"Cellular focal segmental glomerulosclerosis: clinical and pathologic features","volume":"70","author":"Stokes","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2008.356_bb0315","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1681\/ASN.V10151","article-title":"The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy","volume":"10","author":"Barisoni","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2008.356_bb0320","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","article-title":"Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl disphosphate (FPP) synthase in the kidney: Implications for renal safety","volume":"22","author":"Luhe","year":"2008","journal-title":"Toxicol In Vitro"},{"key":"10.1038\/ki.2008.356_bb0325","first-page":"5294","article-title":"The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway","volume":"58","author":"Shipman","year":"1998","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2008.356_bb0330","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/j.ajkd.2006.02.189","article-title":"Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: Mitochondrial toxicity as a pathogenetic concept?","volume":"47","author":"Sauter","year":"2006","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815532006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815532006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T11:04:52Z","timestamp":1631617492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815532006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0085253815532006"],"URL":"https:\/\/doi.org\/10.1038\/ki.2008.356","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}